Nemes Rush Group LLC Editas Medicine, Inc. Transaction History
Nemes Rush Group LLC
- $689 Billion
- Q3 2024
A detailed history of Nemes Rush Group LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Nemes Rush Group LLC holds 50 shares of EDIT stock, worth $153. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50
Previous 50
-0.0%
Holding current value
$153
Previous $234,000
58.55%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding EDIT
# of Institutions
244Shares Held
57.8MCall Options Held
494KPut Options Held
417K-
Black Rock Inc. New York, NY7.78MShares$23.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.68MShares$20.5 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$18.4 Million0.92% of portfolio
-
State Street Corp Boston, MA4.59MShares$14.1 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.46MShares$7.55 Million0.01% of portfolio
About Editas Medicine, Inc.
- Ticker EDIT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 68,737,200
- Market Cap $211M
- Description
- Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...